SLU-PP-332 (Pan-ERR Agonist Exercise Mimetic)

📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.

Mechanism of Action — Pan-ERR Agonism Drives Exercise-Adaptation Transcription

SLU-PP-332 is the most-cited synthetic small-molecule ERR pan-agonist in the published literature. ERRs (estrogen-related receptors α, β, γ) are orphan nuclear receptors that share the DNA-binding domain of estrogen receptors but do not bind estrogen — they are constitutively active in the absence of any natural endogenous ligand and instead are regulated by coactivator-binding (most importantly PGC-1α). ERRs are the principal transcriptional drivers of:

• Mitochondrial biogenesis — direct transcriptional control of TFAM, NRF1, NRF2, and dozens of mitochondrial-protein-import genes
• Fatty-acid β-oxidation — induction of CPT1B (carnitine palmitoyltransferase 1B), MCAD, LCAD, and other β-oxidation enzymes
• Oxidative phosphorylation — transcription of nuclear-encoded ETC complex subunits
• Oxidative-fibre development — Type IIa (oxidative fast-twitch) myosin heavy chain induction; conversion from glycolytic Type IIb fibres to oxidative Type IIa fibres
• Glucose-handling adaptation — improved skeletal-muscle insulin sensitivity in DIO mouse models

This is the same transcriptional programme that is engaged by PGC-1α-driven exercise adaptation — making pan-ERR agonism a direct pharmacological route to the exercise-adaptation phenotype. The Billon et al. (2023) ACS Chemical Biology paper demonstrated that acute single-dose SLU-PP-332 produces a gene-expression signature in mouse skeletal muscle that overlaps substantially with the signature produced by a bout of voluntary wheel-running — and chronic dosing (50 mg/kg/d IP for 4 weeks) increases Type IIa fibre proportion and treadmill endurance in mice. Follow-up work (Billon et al. 2024, alleviation of metabolic syndrome) has demonstrated metabolic-improvement effects in DIO mice including glucose-tolerance improvement and reduced hepatic steatosis.

Published Evidence

• Pan-ERR receptor pharmacology — canonical reference small-molecule ERR pan-agonist
• Exercise-mimetic transcriptional studies — published as the leading “exercise in a pill” compound alongside AICAR; mechanistically distinct (ERR-direct vs AMPK-AMP-mimetic)
• Mitochondrial biogenesis studies — direct transcriptional driver of TFAM / NRF1 / NRF2 axis
• Skeletal-muscle adaptation studies — Type IIa oxidative-fibre induction, endurance-performance phenotype
• Metabolic-syndrome studies — DIO mouse models, hepatic steatosis, insulin sensitivity
• PGC-1α pathway pharmacology — engages PGC-1α-driven transcriptional cascade from downstream

For broader context see AICAR (canonical AMPK-mediated exercise mimetic — different mechanism), AOD-9604 (lipolytic-only fat-loss peptide), MOTS-c (mitochondrial-derived peptide), 5-Amino-1MQ (NAD-axis NNMT inhibitor), NAD⁺ (electron-transport coenzyme).

Available Strengths

How It Compares — SLU-PP-332 vs AICAR

SLU-PP-332 and AICAR are the two most-cited “exercise mimetic” compounds in this catalogue, but they engage the exercise-adaptation programme through mechanistically distinct upstream routes. SLU-PP-332 directly activates the ERR family (the downstream transcription factor for the mitochondrial-biogenesis programme). AICAR activates AMPK (the upstream energy-sensor kinase that, among many other effects, drives PGC-1α expression and PGC-1α-ERR co-activation). The two compounds therefore converge on the same downstream gene-expression signature but engage it from different points of the regulatory cascade.

Storage and Reconstitution

Lyophilized vials: store at 2–8 °C short-term, −20 °C long-term. Reconstitute in DMSO at ≥10 mg/mL working stock (aqueous solubility is limited; DMSO is the preferred solvent). For in-vivo work, formulate with co-solvents (DMSO/PEG-400/saline or similar) just before administration. Store DMSO stocks at −20 °C, single-thaw use. Protect from light. Avoid repeated freeze-thaw.

FAQ

Is “SLU-PP-322” the same as SLU-PP-332?

Some supplier batches use “SLU-PP-322” and “SLU-PP-332” interchangeably for the same Burris-lab ERR pan-agonist. The canonical scientific designation is SLU-PP-332 (Billon et al. 2023, ACS Chemical Biology), with CAS 303760-60-3. Consult batch COA for definitive identification.

What published dose ranges have been used?

Mouse in-vivo protocols use 50 mg/kg/d IP for 4–8 weeks (Billon et al. canonical protocol). In-vitro myotube and primary muscle-cell pharmacology uses 100 nM to 10 µM in growth medium. EC₅₀ on ERRα is ~98 nM.

How is SLU-PP-332 different from other exercise mimetics?

SLU-PP-332 directly activates ERRs — the downstream transcription factors. AICAR activates AMPK (upstream kinase). The 2010s-vintage PPARδ agonists (GW501516) activate a different but partially-overlapping transcriptional programme. Different mechanism, partially-overlapping output.

Is SLU-PP-332 on the WADA Prohibited List?

Not currently under its specific name, but the broader S4 class (Hormone and Metabolic Modulators) includes exercise-mimetic compounds. The compound’s regulatory status may evolve as more data accumulates. Users in human-subject contexts should consult the current WADA list.

Other Exercise-Mimetic / Metabolic Compounds

• AICAR — Canonical AMPK-mediated exercise mimetic — complementary mechanism
• AOD-9604 — Lipolytic-only hGH C-terminal fragment
• MOTS-c — Mitochondrial-derived metabolic peptide AMPK activator
• 5-Amino-1MQ — NNMT inhibitor — NAD-axis precursor sparing
• NAD⁺ — Direct dinucleotide pool supplementation
• BAC Water (Bacteriostatic Water) — Required for reconstituting any lyophilized vial — sterile, 0.9% benzyl-alcohol-preserved diluent

More options in Peptides

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Retatrutide

US$150.00 – US$2,062.50Gama de preços: US$150.00 a US$2,062.50

Tirzepatide

US$105.00 – US$2,212.50Gama de preços: US$105.00 a US$2,212.50

BAC Water (Bacteriostatic Water)

US$50.00 – US$150.00Gama de preços: US$50.00 a US$150.00

HCG (Human Chorionic Gonadotropin) — Pharmaceutical Grade

US$255.00 – US$1,162.50Gama de preços: US$255.00 a US$1,162.50